What 'Pre-Qualified' Should Mean for an IVD Clinical Site

“Pre-qualified network” is one of the least standardized phrases in clinical research. At one end it means sites that are contracted, IRB-experienced, IVD-trained, and ready to enroll on a known protocol. At the other end it means a list of clinics that once expressed interest.

Both get described the same way in a proposal. Here is how to tell them apart before you sign.

The questions that separate real from nominal

Are the sites contracted today, or will they be contracted after we sign? This is the single most revealing question. Master service agreements already in place mean activation is protocol-specific work. If contracting starts after your kickoff, that negotiation is inside your timeline.

Have these sites run an IVD protocol before? Diagnostic studies have their own rhythm: single-visit enrollment, specimen handling, device accountability, often no follow-up. A site fluent in oncology trials may still be learning yours.

What is the IRB situation? Sites with an existing IRB relationship, or a network operating under a standing protocol, move materially faster than sites setting one up for the first time.

Who staffs the study at the site? If the answer is “the clinic’s existing staff, in addition to their day jobs,” expect enrollment to compete with patient care and lose. Embedded coordinators exist precisely to prevent that.

Can they supply intended use operators? For any waived-setting device this is decisive. Professional research coordinators are the wrong population for a CLIA waiver study. You need untrained everyday clinic staff, and most traditional research sites cannot provide them.

What qualification should actually cover

A network worth the label has verified, before your study exists:

• Executed contracts and agreed budget frameworks.
• Patient volume in the relevant population, confirmed rather than estimated.
• Equipment, storage, and specimen handling capability.
• Staff availability, and whether the operators match the pathway.
• CLIA status appropriate to the testing complexity involved.
• IRB relationship and documented regulatory history.
• Geographic and demographic spread across the network as a whole.

That last one is easy to overlook and matters to reviewers. FDA expects performance data that reflects a representative population. A network of twenty sites clustered in two metro areas can satisfy a site count and still fail the underlying intent.

Count is the least interesting number

A network’s headline figure tells you almost nothing on its own. What matters is composition: how many of those sites match your intended use profile, serve your target population, and can supply your required operators.

Ten genuinely matched sites will out-enroll a hundred nominal ones. When a network is presented as a single large number, the useful follow-up is simply: how many of these would you actually propose for this study, and why those?

A fair caveat

No network is pre-qualified for everything. A device targeting a rare condition, an unusual specimen type, or a specialized population will need site work specific to your study no matter who you engage. Any CRO claiming otherwise is overselling.

The honest version of the claim is narrower and more useful: for common IVD study designs in point-of-care, urgent care, and home-use settings, the qualification work is already done, so activation is weeks rather than months. Where your study falls outside that, you should expect to hear so up front.

---

Studybox maintains over 100 pre-qualified sites across point-of-care, urgent care, and home-use settings, contracted in advance and staffed by embedded coordinators. If you want to know how many of them fit a specific intended use profile, ask us and we will give you the real number rather than the headline one.